Buy the Dip, Watch the Print: A Mid-Window Trade on Tarsus (TARS)
Tarsus (TARS) looks buyable around current levels after a run-up into earnings fear. Strong commercial traction for XDEMVY (2025 sales $451.4M; 2026 guidance $670-700M), ultra-high gross margins (~93%), and modest leverage argue for buying a disciplined swing that survives an earnings wobble and targets mean-reversion toward the $80s. Technicals sh…